Navigation Links
Accera Reaches 75% Enrollment in the Phase 3 NOURISH AD Study of AC-1204 for the Treatment of Alzheimer's Disease
Date:7/14/2015

BROOMFIELD, Colo., July 14, 2015 /PRNewswire/ -- Accera, Inc. today announced that it has achieved 75% enrollment for its NOURISH AD Phase 3 clinical study of AC-1204 for the treatment of Alzheimer's disease. The study has a total planned enrollment of approximately 480 patients and is the first of two Phase 3 trials of AC-1204, an investigational new drug designed to address the metabolic defect of the brain observed in Alzheimer's patients.

"The NOURISH AD trial is progressing well, and we expect to complete enrollment mid-next year," said Accera's President and CEO, Dr. Charles Stacey. "The repeated failure of pipeline drugs for Alzheimer's disease emphasizes the need to explore new mechanisms in order to identify new options for patients. The NOURISH AD study represents a differentiated approach to tackling this disease."

"Instead of addressing amyloid or tau, AC-1204 addresses the metabolic defects seen in the disease," added Samuel Henderson, Ph.D., Accera's vice president of research and development and the study's director. "The only way we can beat Alzheimer's is by testing new drugs in studies like NOURISH AD. We are grateful for the support of all of the patients, caregivers and investigators who have joined us in the effort to find new treatments."

About the NOURISH AD Phase 3 Clinical Study

NOURISH AD is a 26-week, double-blind, randomized, placebo-controlled, parallel-group study investigating the effects of daily administration of AC-1204 in subjects with mild to moderate Alzheimer's disease, with an optional 26-week open-label extension. Conducted at up to 90 sites, the study is currently enrolling patients with an anticipated total of approximately 480 enrolled. The primary and key secondary endpoints will examine the effects of AC-1204 on memory and cognition as measured by the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-Cog) and global function as measured by the Alzheimer's Disease Study Cooperative Study – Clinicial Global Impression of Change (ADCS-CGIC) after 26 weeks among non-carriers of the epsilon 4 variant of the gene apolipoprotein E (APOE4). The study will also evaluate activities of daily living, resource utilization and quality of life among subjects with mild-to-moderate Alzheimer's.

For more information, visit https://www.AD-trial.com

About Accera

Accera, Inc. is a clinical-stage biotechnology company based in Broomfield, Colorado, developing therapies for central nervous system disorders. The company's proprietary scientific platform addresses unmet medical needs in brain health, including Alzheimer's disease. From its roots in developing a marketed product, Axona®, Accera has advanced to the clinical development of drugs with innovative mechanisms of actions. The company's management team includes globally recognized specialists in central nervous system diseases and drug development, who together leverage the latest scientific knowledge and understanding of neurological disorders. Accera's lead product candidate is AC-1204, a ketosis-inducing compound in a Phase 3 clinical study in patients with mild to moderate Alzheimer's disease.

For more information, visit www.accerapharma.com.

Accera Media Contacts:                                                  

Russo Partners LLC 

Todd Davenport, Ph.D.
(212) 845-4235                                                        
todd.davenport@russopartnersllc.com

David Schull                                                             
(212) 845-4271
(858) 717-2310 Mobile                                                                                david.schull@russopartnersllc.com                       


'/>"/>
SOURCE Accera, Inc.
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. Accera Appoints Charles Stacey, M.D., as President and CEO
2. Enrollment in Relmada Therapeutics Proof-of-Concept Clinical Study for Novel Oral Formulations of Buprenorphine Reaches Halfway Mark
3. Report: Proteomics Research Market Reaches $1.6 Billion
4. Report: U.S. Out-of-Pocket Healthcare Spending Reaches $416 Billion
5. Kalorama: Global Medical Device Market Reaches $360 Billion
6. Transvaginal Mesh Settlement News: Boston Scientific Reaches First TVM Settlement, Says Lawsuitsettlementnews.com
7. Medicare Advantage Enrollment Reaches 17 Million According to Mark Farrah Associates
8. Ultra Clean Systems Reaches Exclusive Place within Robotic Surgical Instrument Cleaning Industry with Latest Certifications
9. Block & Leviton LLP Investigates Hospira, Inc. for Possible Breaches of Fiduciary Duty in Connection with Their Proposed Acquisition by Pfizer Inc.
10. Malaria No More Reaches Power Of One Campaign Goal for Treatments In Zambia
11. MediciGlobals Alzheimers Community Reaches 200,000 likes and more than half a million weekly visitors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/19/2019)... Pa. (PRWEB) , ... February 19, 2019 , ... ... Healthcare firms of all sizes, announces the hiring of Frank Iafrato as Director of ... work to deepen the firm’s sales coverage throughout the Northeast region, building upon the ...
(Date:2/19/2019)... ... February 19, 2019 , ... Clearwater Dental Associates is opening ... do not have the proper amount of bone to support a dental implant long-term. ... improve the strength of the jaw bone. , Gum disease and untreated tooth loss ...
(Date:2/19/2019)... CALABASAS, Calif. (PRWEB) , ... February 19, 2019 , ... ... missing teeth in Calabasas, California, to make an appointment at her Simi ... “gold standard” of tooth replacement, as they can last 20 years or longer with ...
Breaking Medicine Technology:
(Date:2/19/2019)... ... 19, 2019 , ... Tap water issues in the Jacksonville ... FL proudly serving over 3,500 satisfied customers. I’m looking forward to seeing the ... selling and installing our popular Water Filtration Systems," says Bob Novak, President of ...
(Date:2/19/2019)... ... February 19, 2019 , ... End2End™, a breakthrough patient journey ... experiences. Through the End2End solution, health systems are able to leverage four ... Access Manager enhances engagement through robust conversion, scheduling and pre-arrival management. , ...
(Date:2/19/2019)... ... 2019 , ... NCPDP announced today that Dave deBronkart, ... deliver the luncheon keynote on Tuesday, May 7, at its 2019 Annual ... partnerships between patients and their medical providers to NCPDP’s Annual Conference, May 6-8, ...
(Date:2/19/2019)... NEW YORK (PRWEB) , ... February 19, 2019 , ... ... has completed her book “Dexascan: Beyond a Missed Opportunity”: an autobiographical work offered to ... screenings that provide early detection. , Kidd shares, “On September 28th of 2013, ...
(Date:2/17/2019)... ... February 16, 2019 , ... Nabila K® Cosmetics, a worldwide ... the current trend for minimal packaging that allows the product to take center stage. ... typography to tell its story. Presenting a consistent design throughout each of its ...
Breaking Medicine News(10 mins):